|
Ikena Oncology ، Inc. (IKNA) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Ikena Oncology, Inc. (IKNA) Bundle
تُمكّنك حاسبة DCF (IKNA) التي تم تصميمها من أجل الدقة (IKNA) من تقييم تقييم Ikena Oncology ، Inc. باستخدام البيانات المالية في العالم الحقيقي ، مما يوفر مرونة كاملة لتعديل جميع المعلمات الأساسية للتوقعات المحسنة.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.8 | 9.2 | 31.0 | 15.6 | 9.2 | 8.6 | 8.1 | 7.6 | 7.1 | 6.7 |
| Revenue Growth, % | 0 | -33.15 | 237.01 | -49.59 | -41.35 | -6.02 | -6.02 | -6.02 | -6.02 | -6.02 |
| EBITDA | -18.2 | -44.2 | -33.6 | -70.2 | -74.4 | -8.6 | -8.1 | -7.6 | -7.1 | -6.7 |
| EBITDA, % | -132.69 | -480.95 | -108.42 | -449.18 | -812.19 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .1 | 1.3 | 1.7 | 2.0 | 1.0 | .8 | .7 | .7 | .6 | .6 |
| Depreciation, % | 0.88708 | 13.75 | 5.54 | 13.02 | 11.14 | 8.87 | 8.87 | 8.87 | 8.87 | 8.87 |
| EBIT | -18.4 | -45.5 | -35.3 | -72.2 | -75.4 | -8.6 | -8.1 | -7.6 | -7.1 | -6.7 |
| EBIT, % | -133.58 | -494.7 | -113.96 | -462.2 | -823.33 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 82.1 | 162.5 | 232.2 | 156.9 | 175.5 | 8.6 | 8.1 | 7.6 | 7.1 | 6.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | .9 | 2.1 | 2.4 | 2.1 | 2.1 | 1.3 | 1.2 | 1.1 | 1.1 | 1.0 |
| Accounts Payable, % | 6.8 | 23.08 | 7.69 | 13.4 | 22.55 | 14.71 | 14.71 | 14.71 | 14.71 | 14.71 |
| Capital Expenditure | -.3 | -.8 | -1.8 | -1.4 | -.4 | -.5 | -.5 | -.5 | -.4 | -.4 |
| Capital Expenditure, % | -2.3 | -8.33 | -5.68 | -9.16 | -4.52 | -6 | -6 | -6 | -6 | -6 |
| Tax Rate, % | 0.23709 | 0.23709 | 0.23709 | 0.23709 | 0.23709 | 0.23709 | 0.23709 | 0.23709 | 0.23709 | 0.23709 |
| EBITAT | -18.4 | -45.5 | -35.3 | -69.9 | -75.2 | -8.6 | -8.0 | -7.6 | -7.1 | -6.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -17.6 | -43.8 | -35.1 | -69.6 | -74.7 | -9.1 | -7.9 | -7.4 | -7.0 | -6.5 |
| WACC, % | 5.94 | 5.94 | 5.94 | 5.92 | 5.94 | 5.94 | 5.94 | 5.94 | 5.94 | 5.94 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -32.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -7 | |||||||||
| Terminal Value | -169 | |||||||||
| Present Terminal Value | -127 | |||||||||
| Enterprise Value | -159 | |||||||||
| Net Debt | -109 | |||||||||
| Equity Value | -50 | |||||||||
| Diluted Shares Outstanding, MM | 42 | |||||||||
| Equity Value Per Share | -1.20 |
What You Will Get
- Comprehensive IKNA Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Ikena Oncology’s future performance.
- User-Friendly Design: Crafted for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive Ikena Financials: Gain access to precise pre-loaded historical data and future forecasts.
- Adjustable Forecast Parameters: Modify highlighted cells for metrics such as WACC, growth rates, and profit margins.
- Real-time Calculations: Automatic adjustments for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly charts and summaries to illustrate your valuation findings.
- Designed for All Levels: An intuitive layout suitable for investors, CFOs, and consultants alike.
How It Works
- Download: Obtain the comprehensive Excel file featuring Ikena Oncology, Inc. (IKNA) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and compare results instantly.
- Make Decisions: Utilize the valuation outcomes to inform your investment strategy.
Why Choose This Calculator for Ikena Oncology, Inc. (IKNA)?
- User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters effortlessly to suit your analytical needs.
- Real-Time Valuation: Instantly observe changes to Ikena's valuation as you modify the inputs.
- Preloaded Data: Comes with Ikena's actual financial metrics for immediate analysis.
- Endorsed by Experts: Widely utilized by investors and analysts for sound decision-making.
Who Should Use Ikena Oncology, Inc. (IKNA)?
- Investors: Make informed decisions in the biotech sector with our cutting-edge insights.
- Healthcare Analysts: Streamline your research with comprehensive data on oncology innovations.
- Consultants: Easily modify our resources for client discussions or strategic reports.
- Biotech Enthusiasts: Enhance your knowledge of cancer therapies through detailed case studies.
- Educators and Students: Utilize our materials as a hands-on resource in life sciences education.
What the Template Contains
- Pre-Filled Data: Includes Ikena Oncology's historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Ikena Oncology’s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.